NCT04234698View on ClinicalTrials.gov

Patient Characteristics, Treatment Patterns And Incidence Of Events (Discontinuation, Persistence, Key Primary Clinical Outcomes) In NVAF Patients Initiating OAC Therapy In Colombia

CompletedOBSERVATIONAL
Enrollment

2,076

Participants

Timeline

Start Date

March 22, 2021

Primary Completion Date

October 31, 2021

Study Completion Date

October 31, 2021

Conditions
Atrial Fibrillation
Trial Locations (1)

111211

Pfizer Investigational Site, Bogota

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04234698 - Patient Characteristics, Treatment Patterns And Incidence Of Events (Discontinuation, Persistence, Key Primary Clinical Outcomes) In NVAF Patients Initiating OAC Therapy In Colombia | Biotech Hunter | Biotech Hunter